A Phase II Neoadjuvant Trial of Sunitinib Malate (SU011248) Plus Hormonal Ablation for Patients Who Have High Risk Localized Prostate Cancer and Will Undergo Prostatectomy
Latest Information Update: 09 Dec 2024
At a glance
- Drugs Sunitinib (Primary) ; Leuprorelin
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
Most Recent Events
- 23 May 2024 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 23 May 2024 Planned primary completion date changed from 31 Dec 2024 to 31 Dec 2025.
- 12 Oct 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.